Gujarat Themis Biosyn Limited share price
NSE: GUJTHEM · ISIN INE942C01045
Key numbers
- Market cap
- ₹ 5,427 Cr
- Current price
- ₹ 417.00
- 52-week high / low
- ₹ 479 / 225
- Stock P/E
- 93.3
- Book value
- ₹ 26.4
- Dividend yield
- 0.16%
- ROCE
- 18.0%
- ROE
- 17.4%
- Debt to equity
- 0.56
- Sales growth (3 yrs)
- 3.8%
- Profit growth (3 yrs)
- -7.0%
- 1-year return
- 1.3%
About Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O, an antibiotic for the treatment of traveller's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 36 | 42 | 43 | 44 | 44 |
| Operating profit | 14 | 21 | 21 | 19 | 21 |
| Net profit | 9 | 14 | 12 | 11 | 11 |
| EPS (₹) | 0.83 | 1.31 | 1.14 | 1.00 | 1.02 |
Concall summary (2026-08-14)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Going forward, we aim to progressively move downstream into APIs and other high -value products, thereby capturing a larger share of the pharmaceutical value chain.
- Revenue from operations for Q1 FY27 stood at INR43.8 crores compared with INR35.9 crores in the corresponding quarter last year, an increase of 22.1% year -on-year.
Growth & demand
- It gives me great pleasure to address you all today as GTBL stands at an important transformational juncture in its growth journey.
- This growth came in from a robust increase in sales volumes, which reflects a healthy demand outlook for our products.
Margins & costs
- Now if you take the modest cost of capital around 10%, then it will create around INR200 crores of interest burden every year.
- And with regards to the interest cost, while the interest percentages are significantly higher in India, in the two geographies that we are looking at, the interest cost is significantly lower than the 10% that you have mentioned.
Capex & expansion
- Our ongoing multiphase capital expenditure program is expanding our fermentation infrastructure, strengthening our R&D capabilities and creating downstream API manufacturing capacity.
- Complementing our technology expansion is acquisition of selected global brands from Sanofi France.
Balance sheet & cash
- So we are raising around INR1,000 crores through QIP and taking a debt of around INR2,000 crores.
- And then we will figure out exactly whether we raise INR1,000 crores or how do we go about the debt -- sorry, what do we do with regards to the debt part.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.